Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of olezarsen in severe hypertriglyceridemia
MOH_2022-10-25_012141Phase 3Not yet recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olezarsen in hypertriglyceridemia (4 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percent change in fasting triglycerides from baseline. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on MOH_2022-10-25_012141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-25_012141.